Where: Building 9 Lecture hall 1
Credit: 1
Description
Lecture by Zhen Gu, Professor in the Department of Bioengineering and Director of the NIH Biotechnology Training in Biomedical Sciences and Engineering Program at UCLA.
ABOUT THIS EVENT
Spurred by recent advances in materials chemistry, molecular pharmaceutics, and nanobiotechnology, stimuli-responsive “smart” systems offer opportunities for precisely delivering drugs in dose-, spatial- and temporal-controlled manners. In this talk, Professor Gu will discuss their ongoing efforts in developing physiological signal-triggered bioinspired drug delivery systems. He will first present the glucose-responsive synthetic systems for the biomimetic delivery of insulin for diabetes treatment. Bioresponsive microneedle patches and vesicle fusion-mediated synthetic beta cells will be emphasized. He will further discuss the local and targeted delivery of immunomodulatory therapeutics for enhanced cancer therapy. His latest study utilizing platelets, cell conjugates and gels for delivery of immune checkpoint inhibitors will be specifically introduced.
Check out this event’s photo gallery!
Watch this lecture!
Zhen Gu
Zhen Gu is a Professor in the Department of Bioengineering and Director of the NIH Biotechnology Training in Biomedical Sciences and Engineering Program at the University of California, Los Angeles (UCLA). He received his B.S. degree in Chemistry and M.S. degree in Polymer Chemistry and Physics from Nanjing University. In 2010, he obtained a Ph.D. at UCLA. He was a Postdoctoral Associate working with Dr. Robert Langer at MIT and Harvard Medical School from 2010 to 2012. Before he moved to UCLA in 2018, he had been appointed as a Jackson Family Distinguished Professor in the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University. Dr. Gu’s group studies controlled drug delivery, bio-inspired materials, and nanobiotechnology, especially for cancer and diabetes treatment. He has published over 170 research papers and applied over 60 patents. He is a co-founder of five start-up companies.
No resources found.
No links found.
